It is generally accepted that GIST is a potentially malignant tumor, and although surgery is the treatment of choice for primary resectable GIST, the 5-year survival rate of GIST patients after complete resection of the lesion is only about 50%, and the 5-year survival rate of patients with incomplete resection is less than 10% before the targeted drug imatinib has entered clinical use. Based on the results of existing clinical studies, it is currently recommended that patients with intermediate or high risk of recurrence should receive adjuvant therapy with the targeted drug imatinib after surgery. In terms of treatment duration, adjuvant imatinib treatment after surgery is currently recommended for 2 years for intermediate-risk patients and 3 years for high-risk patients. However, it has been observed clinically that in high-risk patients, even after 3 years of postoperative adjuvant imatinib treatment, patients still relapse six months after stopping the drug. A US study is exploring the efficacy of continuous oral imatinib (400 mg/d) for 5 years after surgery. In addition, some studies have shown that the efficacy of adjuvant therapy with imatinib varies among patients with different genetic mutation types, and genetic testing is recommended for patients who are negative for CD117 expression. Currently, the recommended dose of postoperative imatinib adjuvant therapy is 400 mg once daily. Regarding when to start adjuvant therapy, the opinions of European and American scholars differ greatly from those of domestic scholars. European and American scholars believe that the drug should be started as early as possible after surgery. In China, it is generally recommended to wait until patients can eat normally and start taking the drug 10-14 days after surgery for patients who have had most of their stomachs removed, and 5-7 days after surgery for patients who have had their colon and small intestine segments removed.